Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001

NCT06331728 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Peanut Allergy

Interventions

DRUG: IGNX001
DRUG: Placebo

Sponsor

IgGenix Australia Pty Ltd